Valuation: AstraZeneca PLC

Market Cap 256B 219B 204B 187B 352B 24,474B 359B 2,424B 945B 12,265B 960B 939B 40,606B P/E 2026 *
21.1x
P/E 2027 * 18.4x
Enterprise Value 275B 236B 220B 202B 379B 26,323B 386B 2,607B 1,016B 13,192B 1,033B 1,010B 43,674B EV / Sales 2026 *
4.35x
EV / Sales 2027 * 4x
Free-Float
96.63%
Yield 2026 *
2.02%
Yield 2027 * 2.14%
1 day-1.23%
1 week+2.64%
Current month-5.02%
1 month-6.48%
3 months-12.52%
6 months-19.28%
Current year-11.53%
1 week 134
Extreme 134
141.8
1 month 134
Extreme 134
154
Current year 134
Extreme 134
180.45
1 year 125
Extreme 125
180.45
3 years 112.45
Extreme 112.45
180.45
5 years 94.11
Extreme 94.11
180.45
10 years 47.74
Extreme 47.74
180.45
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
-1.23%+2.64% - - 254B
-2.81%+2.93%+76.40%+127.73% 1,141B
-2.21%+2.02%+49.50%+55.01% 659B
-1.56%+4.39%+25.19%+74.39% 470B
+1.20%+1.72%+42.89%+45.78% 366B
-0.61%+1.72%+25.21%+41.34% 302B
+0.32%+3.30%+2.60%+13.42% 254B
-1.95%+3.80%+46.31%+65.66% 239B
-1.10%-1.12%-14.91%-52.66% 207B
-2.82%+3.84%+20.81%+89.04% 183B
Average -1.28%+3.35%+30.44%+51.08% 424.55B
Weighted average by Cap. -1.62%+3.96%+43.82%+70.86%

Financials

2026 *2027 *
Net sales 63.25B 54.15B 50.53B 46.36B 87.12B 6,052B 88.83B 599B 234B 3,033B 237B 232B 10,041B 66.84B 57.23B 53.39B 48.99B 92.06B 6,395B 93.87B 633B 247B 3,205B 251B 246B 10,611B
Net income 12.07B 10.33B 9.64B 8.85B 16.63B 1,155B 16.95B 114B 44.59B 579B 45.32B 44.33B 1,916B 13.72B 11.74B 10.96B 10.05B 18.89B 1,312B 19.26B 130B 50.67B 658B 51.5B 50.38B 2,177B
Net Debt 19.33B 16.55B 15.44B 14.17B 26.62B 1,849B 27.14B 183B 71.4B 927B 72.57B 70.99B 3,068B 11.65B 9.98B 9.31B 8.54B 16.05B 1,115B 16.37B 110B 43.05B 559B 43.75B 42.8B 1,850B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-08-20 €140.05 -1.23% 337
26-08-19 €141.80 +3.09% 1,293
26-08-18 €137.55 +1.14% 670
26-08-17 €136.00 +1.00% 1,598
26-08-14 €134.65 -2.21% 4,134
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
164.91USD
Average target price
212.30USD
Spread / Average Target
+28.74%

Quarterly revenue - Rate of surprise